many of them, I am their ‘go-to guy’ for both IP and IT matters. I am a German-qualified lawyer and certified licensing professional. I co-author and edit Newsdienst Compliance, one of Germany’s leading law journals for corporate and compliance managers, where I write on IP, licensing, IT and data protection matters. I also contributed a chapter on healthcare privacy for the second edition of the German Handbook of Pharmaceutical Contracts. I am a lecturer at the Center for Transnational IP, Media and Technology Law and Policy at Bucerius Law School (Hamburg, Germany), and a fellow at the Center for Internet and Society at Stanford Law School, United States. A few words about NEUWERK: NEUWERK is a boutique law firm that was founded in 2016 by a group of former Freshfields lawyers. As of today, our headcount amounts to 33 attorneys, each of them specialised in one of the following legal fields: corporate/M&A, IP/IT, employment law, real estate law, (criminal) compliance and disputes and arbitration. We advise our clients with small, well-rehearsed teams of experts who work hand in hand, seamlessly and efficiently. Our particular setup means that we can provide clients with fast, continuous advice across disciplines without ever losing momentum. We combine the speed and openness of a boutique with the full service and quality of a large law firm. Clients regularly praise us for our pragmatic, hands-on approach – and tell us we are fun to work with! University Clinic of Cologne agrees collaboration with BioNTech 19 Finance Monthly Deal Maker Awards 2023 Germany About Börge My name is Börge Seeger, and I am an IP/IT partner and head of the Life Sciences Group here at NEUWERK in Hamburg, Germany. My practice covers the full range of IP and IT law, including IP licensing and partnering, technology transfers, joint ventures and alliances, software and IT outsourcing projects, data protection and privacy, as well as complex commercial law matters. In addition, I have broad experience in assisting clients from the life sciences sector. I regularly advise biotechnology companies, pharmaceutical companies and medical device manufacturers on product divestitures, licensing arrangements, R&D collaborations, clinical trial agreements and distribution matters, as well as on numerous other issues relating to the development, manufacture and marketing of their products. I recently advised Polpharma Biologics, a leading European biopharmaceutical company, on a global cooperation and licensing agreement for the joint development and marketing of biosimilar Natalizumab with Novartis generics subsidiary Sandoz. I also advised Fresenius on the global outsourcing of large parts of its central IT to Capgemini (encompassing more than 1,000 sites around the globe) and ITG, a German-based specialised radiopharmaceutical company, on a long-term global supply and licence agreement with Novartis subsidiary and French cancer specialist AAA. Clients regularly recommend me as “incredibly responsive” – to
RkJQdWJsaXNoZXIy Mjk3Mzkz